Leaders from Cognizant’s Life Sciences business were asked for their insights in PharmaVoice’s annual Year-in-Preview issue, which tracks trends expected to have a big impact on the pharmaceutical industry in 2019. Barinder Marhok, Associate VP, Head of Life Sciences R&D Practice, and Venture Partner predicted that “2019 is the year that multi-sponsor, multi-vendor collaboration goes viral” and that it will be “a break-out year for patient-focused adaptive trials, real-time risk assessment of trials, and orchestration of on-demand labs.” Click here to read more.
“Conversational interfaces, from voice assistants to chat bots, will become the defacto mechanism for how we search, gather insights, and connect with stakeholders across the ecosystem,” predicted Bryan Hill, Chief Technology Officer. With consumer adoption driving the market, Hill says that “the behavioral data captured from these experiences will fuel the machine learning and cognitive capabilities required for more sophisticated conversations.” Click here to read more.
According to Will Reese, Chief Innovation Officer, the trend toward combination therapies represents unique challenges and opportunities to improve health outcomes. “Patients shouldn’t have to be burdened by the complexity of combination therapies because of corporate reluctance to work together.” Click here to read more.
Pratik Maroo, Chief Digital Officer, agreed as he discussed multi-stakeholder commercial models. “Relationships within the stakeholder ecosystem are changing at a rapid pace and new nontraditional players are emerging,” referring to well-known examples such as CVS-Aetna and Amazon-Berkshire-JPMC combinations. “Companies will need to build new rules of engagement with these players and evolve nontraditional commercial models.” Click here to read more.